Toxic Reactive Oxygen Species Enhanced Synergistic Combination Therapy by Self‐Assembled Metal‐Phenolic Network Nanoparticles

Author:

Dai Yunlu12,Yang Zhen2,Cheng Siyuan2,Wang Zhongliang1,Zhang Ruili1,Zhu Guizhi2,Wang Zhantong2,Yung Bryant C.2,Tian Rui2,Jacobson Orit2,Xu Can2,Ni Qianqian2,Song Jibin2,Sun Xiaolian3,Niu Gang2,Chen Xiaoyuan2ORCID

Affiliation:

1. Engineering Research Center of Molecular‐imaging and Neuro‐imaging of Ministry of Education School of Life Science and Technology Xidian University Xi'an Shaanxi 710126 China

2. Laboratory of Molecular Imaging and Nanomedicine (LOMIN) National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Institutes of Health (NIH) Bethesda MD 20892 USA

3. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen 361005 China

Abstract

AbstractEngineering functional nanomaterials with high therapeutic efficacy and minimum side effects has increasingly become a promising strategy for cancer treatment. Herein, a reactive oxygen species (ROS) enhanced combination chemotherapy platform is designed via a biocompatible metal‐polyphenol networks self‐assembly process by encapsulating doxorubicin (DOX) and platinum prodrugs in nanoparticles. Both DOX and platinum drugs can activate nicotinamide adenine dinucleotide phosphate oxidases, generating superoxide radicals (O2•−). The superoxide dismutase‐like activity of polyphenols can catalyze H2O2 generation from O2•−. Finally, the highly toxic HO free radicals are generated by a Fenton reaction. The ROS HO can synergize the chemotherapy by a cascade of bioreactions. Positron emission tomography imaging of 89Zr‐labeled as‐prepared DOX@Pt prodrug Fe3+ nanoparticles (DPPF NPs) shows prolonged blood circulation and high tumor accumulation. Furthermore, the DPPF NPs can effectively inhibit tumor growth and reduce the side effects of anticancer drugs. This study establishes a novel ROS promoted synergistic nanomedicine platform for cancer therapy.

Funder

National Natural Science Foundation of China

National Institute of Biomedical Imaging and Bioengineering

National Institutes of Health

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3